LON:HIK Hikma Pharmaceuticals (HIK) Share Price, News & Analysis GBX 1,911 0.00 (0.00%) (As of 10/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability About Hikma Pharmaceuticals Stock (LON:HIK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Hikma Pharmaceuticals alerts:Sign Up Key Stats Today's Range 1,898▼ 1,93850-Day Range 1,821▼ 2,08852-Week Range 1,711▼ 2,165Volume244,012 shsAverage Volume520,762 shsMarket Capitalization£4.24 billionP/E Ratio2,985.94Dividend Yield3.24%Price TargetGBX 2,325Consensus RatingModerate Buy Company OverviewHikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.Read More… Retire off just one stock ticker? (Ad)ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...Click here for the ticker >>> Hikma Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks39th Percentile Overall ScoreHIK MarketRank™: Hikma Pharmaceuticals scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingHikma Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageHikma Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Hikma Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Hikma Pharmaceuticals is 2,985.94, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 123.51.Price to Earnings Ratio vs. SectorThe P/E ratio of Hikma Pharmaceuticals is 2,985.94, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 110.09.Price to Earnings Growth RatioHikma Pharmaceuticals has a PEG Ratio of 2.38. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHikma Pharmaceuticals has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for HIK. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldHikma Pharmaceuticals pays a meaningful dividend of 3.28%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthHikma Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Hikma Pharmaceuticals is 9,687.50%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about Hikma Pharmaceuticals' dividend. Sustainability and ESG3.7 / 5Environmental Score-2.61 Short InterestThere is no current short interest data available for HIK. News and Social Media1.8 / 5News Sentiment0.16 News SentimentHikma Pharmaceuticals has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Hikma Pharmaceuticals this week, compared to 2 articles on an average week. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Hikma Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders30.54% of the stock of Hikma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.46% of the stock of Hikma Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Hikma Pharmaceuticals' insider trading history. Receive HIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address HIK Stock News HeadlinesEuropean markets finish lower as car manufacturers struggleSeptember 30 at 6:12 PM | msn.comU.K. stocks lower at close of trade; Investing.com United Kingdom 100 down 1.05%September 30 at 6:12 PM | msn.comRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...October 2, 2024 | Behind the Markets (Ad)Hikma Pharmaceuticals PLC (LON:HIK) Receives GBX 2,325 Average Price Target from AnalystsSeptember 29 at 1:24 AM | americanbankingnews.comWith 55% ownership, Hikma Pharmaceuticals PLC (LON:HIK) boasts of strong institutional backingSeptember 25, 2024 | finance.yahoo.comHikma Pharmaceuticals (LON:HIK) Stock Passes Above 200-Day Moving Average of $1,917.24September 22, 2024 | americanbankingnews.comGlobal stocks rise as investors hopeful of US interest rate cutSeptember 18, 2024 | msn.comUnited Kingdom shares higher at close of trade; Investing.com United Kingdom 100 up 0.37%September 17, 2024 | msn.comSee More Headlines HIK Stock Analysis - Frequently Asked Questions How have HIK shares performed this year? Hikma Pharmaceuticals' stock was trading at GBX 1,789 at the beginning of the year. Since then, HIK stock has increased by 6.8% and is now trading at GBX 1,911. View the best growth stocks for 2024 here. How do I buy shares of Hikma Pharmaceuticals? Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Hikma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hikma Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW) and Athabasca Oil (ATH). Company Calendar Ex-Dividend for 9/20 Dividend8/15/2024Dividend Payable9/20/2024Today10/02/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:HIK CUSIPN/A CIKN/A Webwww.hikma.com Phone+44-20-73992760FaxN/AEmployees9,100Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 2,325 High Stock Price TargetGBX 2,750 Low Stock Price TargetGBX 2,000 Potential Upside/Downside+21.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 0.64 Trailing P/E Ratio2,985.94 Forward P/E Ratio12.40 P/E Growth2.38Net Income£285 million Net Margins9.45% Pretax MarginN/A Return on Equity12.88% Return on Assets9.40% Debt Debt-to-Equity Ratio55.48 Current Ratio1.66 Quick Ratio1.27 Sales & Book Value Annual Sales£3.02 billion Price / Sales1.40 Cash FlowGBX 229.17 per share Price / Cash Flow8.34 Book ValueGBX 1,031 per share Price / Book1.85Miscellaneous Outstanding Shares221,880,000Free FloatN/AMarket Cap£4.24 billion OptionableNot Optionable Beta0.41 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (LON:HIK) was last updated on 10/2/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredThey laughed when he picked Nvidia in 2016…Everyone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredFor Elon, I fear the worst is yet to come…Early last year I predicted that there would be a war on Elon Musk. This hateful rhetoric has led to two s...Porter & Company | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.